中国抗癌协会湖北省淋巴瘤专委会委员，ESCO血液肿瘤专委会中枢淋巴瘤学组委员，湖北省免疫学会青委会委员，湖北省肿瘤微环境专家委员会委员。 主持国家自然科学基金青年项目1项，湖北省重点研发项目1项；省厅级项目3项；获批发明专利1项，国际革新专利1项；发表SCI论文23篇。 1. "The novel thioredoxin reductase inhibitor A-Z2 triggers intrinsic apoptosis and shows efficacy in the treatment of acute myeloid leukemia." Free Radic Biol Med 146: 275-286.（IF:7.37,一作，二区）. 2. Azelaic Acid Exerts Antileukemia Effects against Acute Myeloid Leukemia by Regulating the Prdxs/ROS Signaling Pathway. Oxidative medicine and cellular longevity. 2020;2020:1295984.（IF:6.54,一作，二区）. 3.“Antiproliferative and Immunoregulatory Effects of Azelaic Acid Against Acute Myeloid Leukemia via the Activation of Notch Signaling Pathway.” Front Pharmacol（IF:5.81,一作，二区）. 4.Upfront Treatment of Pediatric High-Risk Neuroblastoma With Chemotherapy, Surgery, and Radiotherapy Combination: The CCCG-NB-2014 Protocol. Front Oncol . 2021 Nov 15;11:745794. (IF:6.24,一作，二区). 5. Pygo2 as a novel biomarker in gastric cancer for monitoring drug resistance by upregulating MDR1. Journal of Cancer. 2021;12(10):2952-9.（IF:4.20,一作，三区）. 6. Leukapheresis and Hyperleukocytosis, Past and Future. International journal of general medicine. 2021;14:3457-67.（IF:2.70,一作，三区）. 7. Dong Y, Zahid KR, Han Y, Hu P, Zhang D. Treatment of Pediatric Inflammatory Myofibroblastic Tumor: The Experience from China Children’s Medical Center. Children. 2022; 9(3):307.（IF:2.80,通讯，三区） 8. Zhang D, Han Y, Dong Y. Can we restart the rituximab after remission of rituximab-induced interstitial lung disease in malignant lymphoma? Ann Hematol. 2022;101(10):2373-5.（IF:4.03,通讯，三区） 9. Han Y, Lian K, Zhang D. Treatment of infantile fibrosarcoma: A tertiary care center experience. Frontiers in pediatrics. 2022;10:1015185.（IF:3.56,通讯，三区） 10. Li Z, Wu Z, Dong Y, Zhang D. Clinical Management of Embryonal Tumor with Multilayered Rosettes: The CCMC Experience. Children (Basel, Switzerland). 2022;9(10).（IF:2.80,通讯，三区） 11.张冬冬,胡鹏超,何忠时,董佑红,廉凯, &段鹏. (2022).儿童肝未分化胚胎性肉瘤临床特点及诊疗分析.湖北医药学院学报(002), 041. 12.张冬冬,董佑红, &袁晓军. (2022).先天性中胚层肾瘤5例临床特点并文献复习.临床儿科杂志(040-006). 专利 1.一种抗急性髓系白血病的化合物及其制备方法与应用；中国专利号：CN201910868746.7，第二名。 2.国际专利：INNOVATION PATENT. Anti-acute-myeloid leukemia compound, preparation method and application thereof.专利号：2019101327，第二名 |
